We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Clinical Application of Whole Exome Sequencing to Identify Rare but Remediable Neurologic Disorders.
- Authors
Kim, Min-Jee; Yum, Mi-Sun; Seo, Go Hun; Lee, Yena; Jang, Han Na; Ko, Tae-Sung; Lee, Beom Hee
- Abstract
Background: The aim of this study was to describe the application of whole exome sequencing (WES) in the accurate genetic diagnosis and personalized treatment of extremely rare neurogenetic disorders. Methods: From 2017 to 2019, children with neurodevelopmental symptoms were evaluated using WES in the pediatric neurology clinic and medical genetics center. The clinical presentation, laboratory findings including the genetic results from WES, and diagnosis-based treatment and outcomes of the four patients are discussed. Results: A total of 376 children with neurodevelopmental symptom were evaluated by WES, and four patients (1.1%) were diagnosed with treatable neurologic disorders. Patient 1 (Pt 1) showed global muscle hypotonia, dysmorphic facial features, and multiple anomalies beginning in the perinatal period. Pt 1 was diagnosed with congenital myasthenic syndrome 22 of PREPL deficiency. Pt 2 presented with hypotonia and developmental arrest and was diagnosed with autosomal recessive dopa-responsive dystonia due to TH deficiency. Pt 3, who suffered from intractable epilepsy and progressive cognitive decline, was diagnosed with epileptic encephalopathy 47 with a heterozygous FGF12 mutation. Pt 4 presented with motor delay and episodic ataxia and was diagnosed with episodic ataxia type II (heterozygous CACNA1A mutation). The patients' major neurologic symptoms were remarkably relieved with pyridostigmine (Pt 1), levodopa (Pt 2), sodium channel blocker (Pt 3), and acetazolamide (Pt 4), and most patients regained developmental milestones in the follow-up period (0.4 to 3 years). Conclusions: The early application of WES helps in the identification of extremely rare genetic diseases, for which effective treatment modalities exist. Ultimately, WES resulted in optimal clinical outcomes of affected patients.
- Subjects
CONGENITAL myasthenic syndromes; GENETIC disorders; PEDIATRIC neurology; SODIUM channel blockers; NEUROLOGICAL disorders; CEREBELLUM degeneration
- Publication
Journal of Clinical Medicine, 2020, Vol 9, Issue 11, p3724
- ISSN
2077-0383
- Publication type
Article
- DOI
10.3390/jcm9113724